Guardant Health stock plunges, Exact Sciences stock soars after colorectal-cancer test study results


Shares of Guardant Health Inc. tanked 40% and shares of Exact Sciences Corp. rallied more than 25% in the extended session Thursday after Guardant announced results from a study using its blood test to screen for colorectal cancer that didn’t appear to surpass Exact Sciences’ stool-sample screening test. Guardant said that the results “pave the way for first potential FDA-approved and Medicare-reimbursed blood test for colorectal cancer screening,” and that it plans to ask for U.S. Food and Drug Administration approval in early 2023. Guardant’s test demonstrated 83% sensitivity in detecting individuals with colorectal…

This article was originally published by Read the original article here.

Previous article: Sam Bankman-Fried scrubbed from Giving Pledge list of billionaire philanthropists
Next articleThursday was a bad day for stocks. Friday’s ‘quadruple witching’ could be worse.


Please enter your comment!
Please enter your name here